WO2018158399A1 - Diagnostic method and system for diagnosis - Google Patents
Diagnostic method and system for diagnosis Download PDFInfo
- Publication number
- WO2018158399A1 WO2018158399A1 PCT/EP2018/055110 EP2018055110W WO2018158399A1 WO 2018158399 A1 WO2018158399 A1 WO 2018158399A1 EP 2018055110 W EP2018055110 W EP 2018055110W WO 2018158399 A1 WO2018158399 A1 WO 2018158399A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- elementary bodies
- sample
- elementary
- bodies
- test composition
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
Definitions
- the invention relates to a method for the diagnosis of a microbial infection in an organism, wherein said microbial infection is at least partially present as inclusion bodies in a cellular environment of the organism.
- the invention further relates to a system for the diagnosis.
- Microbial infections cause a threat to the health of organisms, such as mammals and more particularly human beings.
- a variety of diagnostic methods are available for the identification of such infections. However, such identification may be laborious.
- microbial infections may be asymptomatic, such that an infected host organism is not aware of the infection. This allows spreading of the infection.
- some microbial infections are present intracellular infections.
- inclusion bodies are nuclear or cytoplasmic aggregates of stainable substances, usually proteins.
- the inclusion bodies typically represent sites of viral or bacterial multiplication.
- the inclusion bodies may contain the infectious material in two forms: one form that is suitable for multiplication and another form that is suitable for infection of cells. The latter form may leave the infected cell and spread to enter other cells.
- the one form is also known as a reticulate body and the other form is known as an elementary body.
- the two forms differ in several aspects, such as the RNA/DNA ratio, the density of nuclear material and the type of cell wall.
- the elementary bodies that can survive in extracellular form have a low RNA/DNA ratio, for instance below 1 , have electron- dense nuclear material and a relatively rigid cell wall. They further induce phagocytosis and inhibit phagosome function.
- the reticulate body are thus non- infectious are metabolically active, with a higher RNA/DNA ratio, for instance 3-4. They further have a loosely distributed nucleoid, a thinner more flexible cell wall and replace by binary fission.
- the present invention makes use of the properties of the elementary bodies. While such elementary bodies are known to exist in Chlamydia and Chlamydophila genera, it is not excluded that other microbial infections, for instance virus or gram negative bacteria, spread through a similar mechanism of elementary bodies, i.e.
- inclusion bodies having a form or phase that contains dense nuclear material and is overall relatively rigid so as to enable extracellular existence.
- the presence of inclusion bodies may be due to bacteria that have infected a host organism and more particularly are intracellular bacteria. However, inclusion bodies may also result due to expression of a recombinant gene from one type of organism (such as a eukaryote cell) into another organism, such as a prokaryote cell. Examples of classes of inclusion bodies include viral inclusion bodies, inclusion bodies in red blood cells, inclusion bodies in skin conditions,
- Viral inclusion bodies may be intracytoplasmic, intranuclear, for instance acidophlic or basophilic and furthermore both intranuclear and intracytoplasmic.
- Inclusion bodies in Red Blood Cells may be as developmental organelles, protozoal inclusions and as abnormal haemoglobin precipitates.
- a number of important virus and infections are understood to be in the form of inclusion bodies, including negri bodies in Rabies, Cowdry type A in Herpes simplex virus and Varicella zoster virus, Torres bodies in Yellow fever and Cowdry type B in Polio and adenovirus.
- Examples of viral inclusion bodies in plants include aggregations of virus particles (like those for Cucumber mosaic virus) and aggregations of viral proteins (like the cylindrical inclusions of potyviruses).
- Mycoplasma species infections are understood to be intracellular bacterial infections. In the following, the focus will be on inclusion bodies of bacterial species of the Chlamydia genus.
- Chlamydia trachomatis (hereinafter also abbreviated to CT) is the single most important infectious agent associated with blindness (trachoma); about 84 million worldwide suffer from C.
- Chlamydia species are obligate intracellular bacteria, and are represented in two developmental forms in the host: (1) intracellular non-infectious reticulate Bodies (RBs) representing the bacteria in replicative form, and (2) extracellular Elementary Bodies (EBs) acting as infectious particles that target host cells.
- RB non-infectious reticulate Bodies
- EBs extracellular Elementary Bodies
- EBs are able to internalize in the host cell after interactions between the bacterial outer membrane proteins and different host cell receptors. After internalization, EBs express bacterial inclusion proteins that prevent fusion with lysosomes, and transport to the microtubule- organizing center.
- the EBs differentiate into RBs, which are able to replicate by binary fission and subsequently re- differentiate into EBs at the end of the developmental cycle.
- EBs can exit the cell after lysis of the host cell or via extrusion and may to infect other host cells.
- Chlamydia EBs are recognized by the host organism by receptors of the innate immune systems, called
- NAATs are currently generally considered as the gold standard for CT diagnosis. NAATs do not depend on viable pathogens and higher loads, and are therefore much more sensitive than culture. Most of the NAATs are based on polymerase chain reaction (PCR) and use fluorescence labelled probes to detect the amplified PCR products in real time.
- PCR polymerase chain reaction
- NAATs often target two regions, since problems regarding deletions and recombinant of the target regions including even plasmid free variant have been shown in the past and the plasmid region is the preferred region since it is lOx more present as compare to chromosomal targets.
- NAATs In principle, all relevant clinical materials can be analysed by NAATs, however first void urine is the recommended sample type in men, and vaginal swabs are the recommended sample type for women. Women are more often tested as compared to men based on the late complication burden women have in contract to men. NAATs and culture-based test are usually performed in a central laboratory and require transportation of specimens and transmission of test results to the clinicians. As a consequence, they also require a second visit of the patient. Delayed treatment, or no treatment at all if patients do not re-appear again (especially low social, economic and educational settings), could contribute to the high incidence of infection. It is therefore desired to develop a Rapid diagnostics tests (RDTs) that could be performed near-patient (Point-of-Care).
- RDTs Rapid diagnostics tests
- RDT would further allow immediate antibiotic treatment in case of a positive test and no loss of society on an economical level by a second visit.
- these current RDTs are significantly less sensitive and specific and not implemented anywhere.
- RDT development is top priority to combat CT infections in both developed and underdeveloped countries.
- MALDI-TOF MS i.e. Matrix-Assisted Laser
- WO2009/065580 essentially the same method could further be used to identify viruses, such as Rickettsia and Chlamydia. Thereto, however, ultracentrifugation is needed to obtain the virus in the form of virions in sufficiently large quantities.
- the term 'virion' is known to refer to the virus particle as opposed to the infected cell.
- the virus particle contains a capsid as an outer protein shell.
- the virus particle is decomposed according to a special decomposition process so as to obtain the coat protein of the capsid and dissolve them for incorporation into the matrix crystals.
- the disclosed method is a first step for concentrating the virus particle in a bodily fluid to pellets, and a second step for decomposition of the pellets of virus particles, after which the relevant protein will be present in a supernatant.
- the description is however problematic in more than one aspect.
- No information is presented on said special decomposition process.
- no identification is given what would be sufficiently large quantities.
- Such anyhow appears difficult for an effective and timely detection of Chlamydia.
- the invention provides a method for the diagnosis of a microbial infection in an organism, wherein said microbial infection is at least partially present as elementary bodies in cellular material of the organism, which method comprises the steps of:
- test composition comprising at most a predetermined maximum number of elementary bodies to a MALDI mass spectrometry method to identify presence of the microbial infection.
- the invention provides a system for diagnosis of a microbial infection, which is at least partially present as elementary bodies in cellular material of an organism, comprising in combination (1) means for lysis of a sample of cellular material; (2) separation means for separating of elementary bodies from other material obtained by cell lysis; (3) mixing means for mixing a composition of a matrix material with the thus separated elementary bodies to obtain a test composition comprising said elementary bodies, (4) a dispensing unit for dispensing a volume of said test composition comprising a predetermined maximum of elementary bodies (5) a MALDI mass spectrometer configured for generating a mass spectrum of said test composition, and (6) a processor for generating a mean spectrum from a plurality of mass spectra for individual volumes and for comparing the mean spectrum with a reference, typically from a database.
- the invention comprises a system for identification of elementary bodies, comprising in combination (1) means for lysis of a sample of cellular material; (2) separation means for separating of elementary bodies from other material obtained by cell lysis; (3) mixing means for mixing a composition of a matrix material with the thus separated elementary bodies to obtain a test composition comprising said elementary bodies, (4) a dispensing unit for dispensing a volume of said test composition comprising a predetermined maximum of elementary bodies (5) a MALDI mass spectrometer configured for generating a mass spectrum of said test composition, and (6) a processor for generating a mean spectrum from a plurality of mass spectra for individual volumes.
- the invention relates to the use of the systems of the invention for identification of elementary bodies and/or for diagnosis of a microbial infection.
- the use of the identification of elementary bodies in an organism comprises: (1) providing a sample of cellular material from the organism; (2) processing the sample to obtain a test composition, that is enriched in elementary bodies; (3) subjecting at least part of the test composition to a MALDI mass spectrometry method to identify said one or more elementary bodies.
- the invention is based on the insight, that elementary bodies can be effectively separated from other cellular material so as to obtain a test composition, wherein the proteins in the elementary body are detectable by means of mass spectrometry. More particularly, it is feasible to generate volumes of the test composition comprising a limited number of elementary bodies per volume. The limited number is for instance at most 10, preferably at most 5 and more preferably at most two. One elementary body per volume is most preferred. This allows using mass spectrometry with a high signal to noise ratio. Furthermore, it is feasible to subject a series of volumes to mass spectrometry sequentially. Since each volume has substantially the same content (i.e. a limited and likely predefined number of elementary bodies), it is easy to combine and/or analyse resulting spectra and/or other results in a meaningful manner.
- the concentration of proteins in the elementary bodies is beneficial for diagnosis by means of a MALDI mass spectrometry method.
- a particularly preferred type of MALDI mass spectrometry is known as MALDI-TOF MS, which is abbreviation for matrix-assisted laser desorption/ionization time-of- flight mass spectrometry. This is an emerging technique for high- throughput, cost-effective and rapid microbial identification.
- microbes are identified by comparing their protein fingerprint (i.e. their total protein content) to a reference, typically from a library.
- the method further comprises the step of generating droplets of the test composition, which droplets are the volumes sequentially subjected to the MALDI mass spectrometry method.
- the droplets are typically generated from a microfluidic dispenser chip on the basis of actuation carried out by a known actuator, such as for instance a piezoelectric actuator.
- a known actuator such as for instance a piezoelectric actuator.
- the volume of the droplets is suitably in the range of picoliters, for instance 1-10 picoliters.
- a selection step is carried out after generation of the droplets.
- Such a selection step ensures that each volume has less elementary bodies than the predefined maximum. More particularly, the step is carried out so as to ensure that each volume has contains at least a minimum number of elementary bodies.
- all volumes contain the same number of elementary bodies, and more preferably, this number is one. However, it is not excluded that the number of elementary bodies is greater than one, at least in part of the volumes.
- volumes without elementary bodies are also generated. Such volumes can be used to identify a background.
- the spectrum of such volume without elementary bodies can be subtracted from the spectrum of a volume with one or more elementary bodies. This is deemed to further increase the signal-to-noise ratio.
- the selection step is carried out by optical image analysis.
- the optical image analysis is for instance embodied with a camera.
- Droplets or other volumes that are not selected for measurement by mass spectrometry may be removed from the droplet stream, for instance by means of an electromagnetic shutter.
- the droplets are viewed at a location adjacent to an orifice of the droplet dispenser. The viewed droplet is then to be ejected from the orifice as a free flying droplet upon a next dispensing event.
- the particles are irradiated with a suitable wavelength, so as to effect fluorescence of specific substances in the particles, more particularly aerosol particles.
- a suitable irradiation source is an excitation laser.
- these droplets are selectively not ionized, i.e. not treated with a laser for ionisation.
- optical image analysis is that the optical image of a specific volume may be registered.
- the registration may be either in the form of an image, or optionally in a form of analysis data.
- Such data could for instance be an image showing the contrast, and/or an indication of the number of dots in the image corresponding to the number of elementary bodies.
- the storage in the form of analysis data may be suitable so as to limit the amount of data to be stored.
- the stored image or the analysis data thereof may be used by a processor, so as to generate a sample results based on a plurality of spectra generated by the mass spectrometer. This is feasible, as the image or analysis data thereof can be directly linked to one individual generated spectrum.
- the processor may enter into a specific protocol.
- Such negative result in the optical imaging can either mean that there are no elementary bodies present, or that an error has occurred.
- One part of the protocol is then an algorithm to verify an appropriate set up of the processing and the dispensing. In some embodiments, this may be implemented as the provision of a signal or alarm to an operator. According to another implementation, a predefined number of droplets apparently devoid of elementary bodies may nevertheless be selected. The resulting mass spectrometry is then used for verification of the apparent negative result.
- the processing of the sample into a test composition comprises the steps of cell lysis and of separation of the elementary bodies from other parts of the lysed cell material.
- cell lysis and subsequent separation allows maintaining the integrity of the elementary bodies, while other cellular material, including for instance reticulate bodies and cell membranes is disintegrated into cell debris and then removed.
- a most preferred method is sonication. This method is capable of lysing the cell and destroying various cell parts, while leaving the more rigid elementary bodies intact.
- Another lysing technique such as liquid homogenization, mechanical, electric
- sonication high frequency sound waves shear cells.
- the power used for sonication is for instance in the range of 40-100W, for instance 50-80W.
- it is performed using an ultrasonic bath or an ultrasonic probe.
- the power source attached to the probe generates sound energy electronically, for instance within a range of 20-50 kHz.
- the sonication is carried out in a plurality of periods with intermittent periods.
- vortexing is carried out in between said sonication periods.
- the sonication periods are suitably in the range of 15-40 seconds, such as 20-30 seconds, the intermittent periods may be as short as 0.5-5 seconds. Variations hereof are not excluded.
- These sonication settings are for conventional cell lysis. It was found that such settings result therein that the cell wall is lysed, but the elementary bodies are not lysed.
- the separation step is carried out by a centrifuge.
- This centrifuge treatment is configured so that the elementary bodies end up in the supernatant and separated from the cell debris.
- the composition with the elementary bodies is thereafter
- a centrifuge treatment may be applied, wherein the elementary bodies would be pelletized.
- another separation technique such as filtration and immunomagnetic separation.
- This further concentration of the elementary bodies is understood to increase the resolution of the subsequent measurement by means of MALDI mass spectrometry.
- the present invention carries out a centrifuge treatment after the cell lysis, to remove cell debris from the elementary bodies.
- the separated elementary bodies were processed to obtain pellets.
- a composition comprising a matrix material is added to obtain a test composition.
- matrix assisted laser desorption ionisation Preferred matrix materials are known from EP2210110B1, which is herein included by reference.
- the matrix material is typically provided as a composition in a volatile solvent and furthermore one or more additives.
- An alcohol such as ethanol, is a preferred solvent.
- the additives are for instance present for control of the pH of the test composition.
- the additives for instance include water and a volatile acid, such as trifluoroacetic acid.
- the term 'volatile' is used in the context of the present invention to refer to a compound that can be evaporated at a temperature ranging from room temperature to 100°C.
- MALDI TOF MS a type of MALDI TOF MS, known as single cell MALDI TOF MS. This is a technique, known per se, wherein the sample preparation is such that each sample detected by the mass spectrometer contains material from a single cell.
- the mixing with the composition of the matrix material for use in the MALDI mass spectrometry method is carried out by resuspension of the pelletized elementary bodies. It is observed that in one embodiment, the enrichment of the test composition involves a substantial isolation of the elementary bodies. However, this is not deemed necessary. It may also be that the test composition is enriched with elementary bodies, while other solid matters remain part of the composition.
- the amount of the elementary bodies is at least 50% by weight based on total solid matter in the test composition. More preferably, the amount is at least 70% by weight based on total solids, or even at least 80%.
- the matrix material will be crystallized onto the solid matter, more particularly the elementary bodies.
- a volatile solvent of the composition of the matrix material is evaporated.
- a stream of coated droplets is generated that is also known as an aerosol beam.
- the analyte with the crystallised material on a surface of the one or more elementary bodies is then irradiated with a laser, typically using UV light. This has the effect that the crystallized matrix absorbs the energy of the laser light and transmits it to the elementary bodies; direct irradiation of the elementary body would rather destruct such bodies.
- the droplets are furthermore transmitted from ambient atmosphere into a vacuum atmosphere.
- the vacuum atmosphere is herein an atmosphere at a pressure sufficiently low to allow mass spectrometry. It is a first advantage of the method of the invention, that the sample collection is not considered to be critical. In case of diagnosing CT, a sample may be collected by a patient undergoing the diagnosis or may be collected by a clinician.
- the definition of droplets each containing a predefined limited number of elementary bodies is furthermore helpful as it allows combination of spectra based on individual droplets in a meaningful manner. For instance, a mean spectrum is generated on the basis of a plurality of spectra of individual droplets. The number of spectra is suitably 10-200, for instance 20-100 or 40-80 spectra. This ability to obtain a spectrum with adequate signal-to-noise ratio therewith not merely allows to confirm that there are elementary bodies indicating an infection, but also to identify the type of infection, and more particularly the specific microorganism responsible for the infection.
- the method has been tested and has been found feasible to detect Chlamydia in urine, in an anal swab and a vaginal swab, wherein the pathogen concentration was equal or less than 10 4 CFU/ml, for instance 10 3 CFU/ml, as typical for a swap.
- the present invention has the potential to detect Chlamydia on the basis of the presence of at little as 10 CFU/ml. It will be understood that while the present method is primarily intended for the detection of a microbial infection, such as an infection with CT, it is not excluded that the method is applied for identification of elementary bodies as such. BRIEF INTRODUCTION OF THE FIGURES
- Fig. 1 shows a schematic representation of an apparatus for MALDI mass spectrometry with a preferred pre-treatment for a liquid test composition
- Fig. 2 shows a schematic representation of the particle flow path and mass spectrometer within the apparatus of Fig 1.
- Fig. 3A-B diagrammatically indicates process steps according to one embodiment of the method of the invention, wherein Fig. 3A indicates the generation and selection of droplets and Fig. 3B indicates MALDI TOF mass spectrometry.
- Fig. 4 shows a flow chart for the processing of the sample according to one embodiment of the method of the invention
- Fig. 5 shows a mass spectrum obtained in a preliminary experiment according to the invention DETAILED DESCRIPTION OF ILLUSTRATED EMBODIMENTS
- FIG. 1 shows a schematic representation of a first embodiment of an apparatus for MALDI mass spectrometry.
- Fig. 2 shows in more detail the portion 200 of the apparatus, hereinafter also referred to as a flight path unit 200.
- MALDI mass spectrometry is particularly suitable for identification of biological material.
- biological material is micro-organisms such as bacteria, fungi and viruses.
- Other types of biological material that can be identified with MALDI include for instance blood cells, peptides.
- the apparatus comprises a sample receiver 10, conduits 11, a first mixing unit 12, a second mixing unit 14, and a flight path unit 200.
- the flight path unit comprises a drying chamber 15, an ionization chamber 191 and a time-of-flight tube 194.
- a droplet is ejected by any droplet ejector 16, such as for instance based on a piezoelectric resonator.
- the droplet follows a droplet beam 24 that extends from the drying chamber 15 into the time-of-flight tube 194.
- the droplet beam 24 Upon drying the droplet beam 24 is actually converted into a particle beam 192.
- the particle beam 192 Upon ionization by radiation from a pulse laser 18, the particle beam 192 is converted into a ion beam 195.
- the mass spectrometer - not shown - measures the ions of the ion beam 195 and creates spectra on the basis thereof.
- a sensor 20, 22 for determining a morphology parameter so as to select particles that are ionized by a laser pulse of the pulse laser 18. This is particularly done so as to ionize only those particles that may lead to useful spectrum information.
- the first mixing unit 12 comprises a first mixer 120, a container 122 for solvent and/or antisolvent, such as water, and a detector 124. Rather than one container 122, two separate containers may be present. Sample material that is for instance obtained from a patient, is diluted with the solvent and/or antisolvent in the first mixer 120.
- Detector 124 is suitably an optical detector configured to detect light scattered from individual micro-organisms when the micro-organisms flow through a measurement beam. From a count of micro-organisms that are detected on average per unit of time interval, the density may be determined. Such detector 124 is known per se and is for instance a cytometer or flow cytometer. Particle detector 124 is shown coupled to a control input of first mixer 120. The control mechanism is arranged to increase the amount of solvent and/or antisolvent, until the measured density has dropped to or below a predefined density. Preferably both are added in a predefined ratio. A liquid circulation circuit may be used to circulate the composition until the desired density has been achieved.
- the second mixing unit 14 comprises a second mixer 14 and a matrix material reservoir 142.
- Matrix material reservoir 142 is coupled to the second mixer 140.
- the second mixer 14 is configured to mix the matrix material into the test composition obtained from the first mixing unit 12.
- the droplet generator 16 may be provided with means for evaluation whether a droplet contains a single microorganism or any other number of microorganisms. Such a detecting means may be arranged to view the suspension in a channel prior to ejection by a nozzle.
- the generator 16 may further be provided with means for directing an ejected droplet to a first position or to a second position depending on information obtained from the detecting means. The first position is then a target position, i.e.
- Fig. 3 A shows one embodiment of a droplet generator 16 and the chamber 15 in more detail.
- the flow path of the droplet beam 24 through the chamber 15 may have a vertical orientation.
- the detecting means 161 are arranged to optically sense the droplets upon ejection from the nozzle of the droplet generator 16.
- the sensor 161 is coupled to a selection means 162, preferably an electromagnetic shutter, to remove those droplets that do not contain any microorganism.
- the chamber 15 is provided with temperature controlled walls so as to keep the temperature in the chamber 15 constant. In one embodiment a temperature of 22-30°C is chosen.
- the chamber 15 is further provided with an inlet 165 for gas generating a homogeneously distributed sheath flow.
- the gas comprises for instance air or nitrogen and is controlled with respect to the concentration of water vapor and optionally any solvent.
- the water vapor concentration is controlled, for instance such that the relative humidity is 30% or more.
- the matrix material in a liquid drop crystallizes on the analyte, typically a microorganism, while the drop dries in flight, resulting in a dried particle, which is also referred to as the test sample.
- the drop is launched with a diameter in the range of 30-60 ⁇ .
- the dried particle has an aerodynamic diameter of less than 3.0 ⁇ in a first embodiment, wherein the test sample contains a single bacteria.
- the sheath flow transports the droplets towards the inlet of the aerosol time- of- flight mass spectrometer.
- Fig. 3B illustrates the identification process based on the generated test samples in a particle beam.
- a laser pulse is fired at the dried particle from pulse laser 18. This results in ionization of material from the test sample.
- the ionized material is then accelerated in a ionization chamber 191, in which high voltages are present to accelerate the ionized material.
- the ionized elements passes a charged grid 216.
- individual ions of a ion beam 195 are separated in a drift region 194, that is free of an electric field.
- This drift region is also known as a time-of-flight tube.
- the separated ions are detected by a detector 220.
- the processor that is coupled thereto processes the obtained data to generate a spectrum or data set 230 ('fingerprint') that can be compared with known data sets.
- Such known data sets are typically stored in a library.
- the sample preparation is shown in Fig. 4.
- the starting composition contained A (the said species in the HeLa cells) in a medium M.
- the HeLa cells were lysed by sonication, using three sonication periods each of 20 seconds at 70W, interrupted by intermittent periods of 2 seconds using vortexing. This resulted therein that the elementary bodies (EB) could be collected, while other cell material was destructed to cell debris (D). After the sonication there was thus EB + D in medium (M).
- the cell material was then transferred to a centrifuge, for separation of the cell debris (D) and the elementary bodies (EB).
- Three subsequent steps (CI, C2, C3) were carried out in this example, using increasing spinning rates, i.e. 500 x g, 2500 x g and 15,000 x g.
- CI, C2, C3 Three subsequent steps (CI, C2, C3) were carried out in this example, using increasing spinning rates, i.e. 500 x g, 2500 x g and 15,000 x g.
- CI, C2, C3 Three subsequent steps (CI, C2, C3) were carried out in this example, using increasing spinning rates, i.e. 500 x g, 2500 x g and 15,000 x g.
- EB pellets of elementary bodies.
- the figure refers for sake of simplicity to 1/2D, as if both steps each remove 50%. That is merely schematically and not a hard requirement.
- the figure shows a specific embodiment for characterization of the method of the invention, it will be understood that when used for diagnostic purposes, the use of C. trachomatis and HeLa cells is typically replaced by the use of cells that could contain the C. trachomatis.
- the cells may be mixed with a medium, before the destruction step. Following the destruction step, the elementary bodies EB will be separated from the cell debris and the medium.
- the use of a centrifuge is therein preferred, although the centrifuge may be replaced in part or entirely by other separation techniques, including filtering, membrane filtering and/or activated (para)magnetic beads.
- a test composition was then generated by bringing the pellets of elementary bodies (EB) into contact with a matrix material.
- EB elementary bodies
- Droplets were generated with a droplet generator. Each droplet has a volume in the range of 10-100 picoliter.
- An image sensor more particularly a camera, was provided at a location so as to enable recording of the droplets at the exit of the droplet dispenser. The image sensor was coupled to a processor to check whether dot-shaped elements, typically darker than other parts of the droplet were present in the droplet. A droplet was selected when the droplet contained one dot-shaped element. If a droplet was not selected, it was taken out of a droplet beam by means of an electro-magnetic shutter. The droplets thereafter passed a drying section. This resulted in the generation of coated particles suitable for MALDI mass spectrometry.
- MALDI mass spectrometry on the individual droplets was thereafter carried out. Mass spectra of individual droplets were generated. The spectra contained a sufficient signal were accumulated, such that signal-to-noise ratio became sufficiently large to distinguish 20-30 significant peaks within the spectrum.
- the base line which corresponds with the spectral level caused by a signal part that varies from particle to particle, is subtracted from the signal. The intensity has been normalized with local variance of the height of the base line. A peak with an intensity of at least one is considered sufficiently significant. The spectrum shown in Fig. 5 was obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880015488.1A CN110402392A (en) | 2017-03-02 | 2018-03-01 | Diagnostic method and diagnostic system |
EP18707053.7A EP3589953A1 (en) | 2017-03-02 | 2018-03-01 | Diagnostic method and system for diagnosis |
BR112019018198-9A BR112019018198A2 (en) | 2017-03-02 | 2018-03-01 | DIAGNOSTIC METHOD AND SYSTEM FOR DIAGNOSIS |
US16/486,112 US20200232984A1 (en) | 2017-03-02 | 2018-03-01 | Diagnostic Method and System for Diagnosis |
JP2019547384A JP2020510829A (en) | 2017-03-02 | 2018-03-01 | Diagnostic method and diagnostic system |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2018460 | 2017-03-02 | ||
NL2018460 | 2017-03-02 | ||
NL2019320 | 2017-07-21 | ||
NL2019320A NL2019320B1 (en) | 2017-03-02 | 2017-07-21 | Diagnostic method and system for diagnosis |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018158399A1 true WO2018158399A1 (en) | 2018-09-07 |
Family
ID=61274284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2018/055110 WO2018158399A1 (en) | 2017-03-02 | 2018-03-01 | Diagnostic method and system for diagnosis |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018158399A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009065580A1 (en) | 2007-11-23 | 2009-05-28 | Bruker Daltonik Gmbh | Identification of pathogens in body fluids |
US20100055677A1 (en) * | 2007-01-04 | 2010-03-04 | The Regents Of The University Of California | Method for genetic identification of unknown organisms |
WO2011067516A1 (en) * | 2009-12-03 | 2011-06-09 | Assistance Publique - Hopitaux De Marseille | Method for quick identification of viruses by means of mass spectrometry |
EP2210110B1 (en) | 2007-11-13 | 2013-03-27 | BiosparQ B.V. | Maldi matrix and maldi method |
EP2836958A1 (en) | 2012-04-10 | 2015-02-18 | BiosparQ B.V. | Method for classification of a sample on the basis of spectral data, method for creating a database and method for using this database, and corresponding computer program, data storage medium and system |
EP2577254B1 (en) | 2010-06-10 | 2015-02-25 | Albert-Ludwigs-Universität Freiburg | Apparatus and method for dispensing cells or particles confined in a free flying droplet |
-
2018
- 2018-03-01 WO PCT/EP2018/055110 patent/WO2018158399A1/en active Search and Examination
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100055677A1 (en) * | 2007-01-04 | 2010-03-04 | The Regents Of The University Of California | Method for genetic identification of unknown organisms |
EP2210110B1 (en) | 2007-11-13 | 2013-03-27 | BiosparQ B.V. | Maldi matrix and maldi method |
WO2009065580A1 (en) | 2007-11-23 | 2009-05-28 | Bruker Daltonik Gmbh | Identification of pathogens in body fluids |
WO2011067516A1 (en) * | 2009-12-03 | 2011-06-09 | Assistance Publique - Hopitaux De Marseille | Method for quick identification of viruses by means of mass spectrometry |
EP2577254B1 (en) | 2010-06-10 | 2015-02-25 | Albert-Ludwigs-Universität Freiburg | Apparatus and method for dispensing cells or particles confined in a free flying droplet |
EP2836958A1 (en) | 2012-04-10 | 2015-02-18 | BiosparQ B.V. | Method for classification of a sample on the basis of spectral data, method for creating a database and method for using this database, and corresponding computer program, data storage medium and system |
Non-Patent Citations (2)
Title |
---|
SIMON K KÜSTER ET AL: "Interfacing droplet microfluidics with matrix-assisted laser desorption/ionization mass spectrometry: label-free content analysis of single droplets", ANALYTICAL CHEMISTRY, 5 February 2013 (2013-02-05), United States, pages 1285, XP055386567, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/ac3033189> DOI: 10.1021/ac3033189 * |
YINGDI ZHU ET AL: "Sensitive and fast identification of bacteria in blood samples by immunoaffinity mass spectrometry for quick BSI diagnosis", CHEMICAL SCIENCE, vol. 7, no. 5, 1 January 2016 (2016-01-01), United Kingdom, pages 2987 - 2995, XP055410693, ISSN: 2041-6520, DOI: 10.1039/C5SC04919A * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014202752B2 (en) | Identification of Pathogens in Body Fluids | |
US10597692B2 (en) | Mass spectrometric diagnosis of sepsis without blood culture | |
AU2010272586A1 (en) | Mass spectrometric diagnosis of septicemia | |
CN113196031A (en) | Rapid natural single cytoplasm analysis method | |
US20200232984A1 (en) | Diagnostic Method and System for Diagnosis | |
Khalil et al. | Flow cytometry sorting to separate viable giant viruses from amoeba co-culture supernatants | |
JP2021509292A (en) | High fidelity bioaerosol condensation capture directly to genomic preservatives | |
CN111655833A (en) | Detection judging device | |
EP3652350A1 (en) | Methods to detect cells latently infected with hiv | |
WO2018158399A1 (en) | Diagnostic method and system for diagnosis | |
WO2021035009A1 (en) | Methods for screening and subsequent processing of samples taken from non-sterile sites | |
CN111601899A (en) | Device having specific cell and nucleic acid number in well and test/calibration method using the same | |
US20240286131A1 (en) | Apparatus | |
EP3885450A1 (en) | Carrier and testing method | |
DE60010776T2 (en) | Improved method for preparation of DNA from serum and plasma | |
CN111334566A (en) | Nucleic acid analysis method, nucleic acid analysis program, and library preparation device | |
Whiteaker et al. | Analysis of Bacillus anthracis spores in milk using mass spectrometry | |
JP2021040499A (en) | Device, kit, evaluating method and determination method | |
EP4092132A1 (en) | Sample for evaluating performance of genetic testing apparatus, method for preparing said sample, and device for evaluating performance, method for evaluating performance, program for evaluating performance, and apparatus for evaluating performance of genetic testing apparatus | |
Pershin et al. | Flow cytometry sorting of cells infected with African swine fever virus | |
CN114574340A (en) | Method, device and kit for manufacturing a device | |
Neiswirth | Role of HCMV in neurological decline of glioma patients during radiochemotherapy-Detection of HCMV in myelomonocytic cells from the peripheral blood of glioma patients | |
WO2022241248A1 (en) | Techniques for releasing cellular contents from a microorganism using a microfluidic system | |
JP2022086982A (en) | Method for manufacturing device, device, and kit | |
Herrera et al. | Strategies of Electron Microscopy in the Diagnosis and Characterisation of Emerging Infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18707053 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2019547384 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019018198 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2018707053 Country of ref document: EP Effective date: 20191002 |
|
ENP | Entry into the national phase |
Ref document number: 112019018198 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190830 |